Membership Home Portfolio Stocks Bonds Funds ETFs CEFs Markets Tools Real Life Finance Discuss
Home>Topics>>Pfizer's Xeljanz Gets Approval, While Lilly's Baricitinib Looks Strong

Pfizer's Xeljanz Gets Approval, While Lilly's Baricitinib Looks Strong

Healthcare Sector and Stocks Analysis from Seeking Alpha

Wed, 21 Nov 2012

By Kevin CC : If you read the briefing documents and listened to the discussion at the arthritis advisory committee on May 9, 2012, then you know both the FDA and advisory panelists had concerns about the 10mg dose of Pfizer's ( PFE ) rheumatoid arthritis (RA) drug Xeljanz (tofacitinib). I ...

Read the rest of this article on Healthcare Sector and Stocks Analysis from Seeking Alpha

Content Partners
Site Directory Site Map Our Products
Corrections Help Advertising Opportunities Licensing Opportunities Glossary RSS Mobile Portfolio Affiliate Careers Company News
International Sites: Australia Canada China France Germany Hong Kong Italy The Netherlands Norway Spain U.K. Switzerland India Finland
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.

© Copyright 2013 Morningstar, Inc. All rights reserved. Please read our Terms of Useand Privacy Policy.Dow Jones Industrial Average, S&P 500, Nasdaq, and Morningstar Index (Market Barometer) quotes are real-time.